Imbalances in chromosome 11q occur in approximately 30% of primary neuroblastoma and are associated with poor outcome. It has been suggested that 11q loss constitutes a distinct clinico-genetic neuroblastoma subgroup by affecting expression levels of corresponding genes. This study analysed the relationship of 11q loss, clinical phenotype and global transcriptomic profiles in four clinico-genetic subgroups (11q alteration/favourable outcome, n ¼ 7; 11q alteration/unfavourable outcome, n ¼ 14; no 11q alteration/favourable outcome, n ¼ 81; no 11q alteration/unfavourable outcome, n ¼ 8; tumours with MYCN amplification and/or 1p loss were excluded). Unsupervised and supervised comparisons of gene expression profiles consistently showed significantly different mRNA patterns between favourable and unfavourable neuroblastomas, both in the subgroups with and without 11q loss. In contrast, favourable tumours with and without 11q loss showed highly similar transcriptomic profiles. Disproportionate downregulation of 11q genes was observed only in unfavourable tumours with 11q loss. The diverging molecular profiles were neither caused by considerable differences in the size of the deleted regions nor by differential methylation patterns of 11q genes. Together, this study shows that neuroblastoma with 11q loss comprises two biological subgroups that differ both in their clinical phenotype and gene expression patterns,
Introduction
Human cancer genomes are characterized by multiple genetic aberrations and epigenetic modifications. Recurrent DNA copy number alterations (CNA) in malignant cells are thought to be critical events in human tumourigenesis, and have been suggested to determine the biological phenotype of the tumour by changing the expression of cancer genes located at the affected sites. The effects of oncogene amplification on mRNA expression levels have been well characterized in various entities and serve as a paradigm for a direct relationship of gene dosage and expression levels in cancer (Savelyeva and Schwab, 2001 ). However, the influence of low-level copy number gains (ofivefold change) and hemizygous losses of large genomic regions on expression levels of the corresponding genes and the global transcriptome is less clear, and its delineation has remained a challenge of cancer research.
In neuroblastoma, several non-random genomic alterations have been described to be closely associated with distinct phenotypes of the disease (reviewed in Fischer et al., 2008) . This paediatric tumour may therefore represent a valuable model to analyse the interactions of CNA and transcriptomic aberrations. A hallmark of neuroblastoma is its biological and clinical heterogeneity, ranging from spontaneous regression of the tumour to relentless progression with fatal outcome of the patients. At diagnosis, these two contrasting subtypes can be largely distinguished by specific chromosomal alterations. Amplification of the oncogene MYCN occurs in B20% of neuroblastomas and is strongly associated with a poor prognosis. More recently, loss of 11q has been reported to be highly correlated with an adverse patients' outcome (Attiyeh et al., 2005; Spitz et al., 2006a) , and has thus been proposed as a stratifying prognostic marker in the International Neuroblastoma Risk Group classification system (Cohn et al., 2009) as well as in the upcoming clinical trial of the Children's Oncology Group (Maris et al., 2007) . As 11q CNA and MYCN amplification are inversely correlated in neuroblastoma, these two genomic alterations have been suggested to delineate two molecularly distinct subgroups (Brodeur, 2003; Bilke et al., 2005) . In contrast, the majority of favourable neuroblastomas lack structural genomic aberrations but show numerical variations of whole chromosomes (Spitz et al., 2006b; Janoueix-Lerosey et al., 2009) . In addition to genomic alterations, the divergent biological and clinical neuroblastoma subtypes show distinct gene expression profiles (reviewed in Fischer et al., 2008) . In a previous study, we have described a prognostic 144-gene expression classifier for neuroblastoma patients using the prediction analysis for microarrays algorithm (PAM) that predicts outcome of neuroblastoma patients with high accuracy .
Together, there is convincing evidence today that both genomic and transcriptomic alterations are associated with the diverging clinical phenotypes of neuroblastoma. However, whereas the effect of MYCN amplification on the transcriptome has been well characterized (Boon et al., 2001; Alaminos et al., 2003; Westermann et al., 2008) , little is known about the interactions of gains or deletions of large genomic regions and gene expression patterns in neuroblastoma. In this study, we aimed to determine the effect of 11q loss on global gene expression patterns and clinical phenotypes in neuroblastoma. For this purpose, we used various bioinformatics strategies in an integrative genomics approach, for which we considered clinical information of neuroblastoma patients as well as whole genome expression profiles, cytogenetic characteristics and promoter methylation data of the tumours.
Results
Gene expression-based classification identifies two prognostically distinct subgroups of neuroblastoma patients with loss of 11q To determine the predictive power of our previously defined 144-gene expression-based PAM classifier in the subset of neuroblastoma with loss of 11q, 61 tumours that had not been included in the original training set and that showed a CNA at 11q were analysed. The PAM classifier predicted 20 patients to be favourable and 41 patients to be unfavourable. Event-free and overall survival of patients with favourable PAM prediction were significantly better than those with an unfavourable prediction (event-free survival at 5 years, 0.79 ± 0.09 vs 0.27 ± 0.09, P ¼ 0.001; overall survival at 5 years, 0.95±0.05 vs 0.64±0.09, P ¼ 0.013; Figures 1a and b) . After exclusion of patients with MYCN amplification (n ¼ 6) from the analysis, the event-free survival of PAM favourable and unfavourable tumours was still significantly different (0.79 ± 0.09 vs 0.31 ± 0.10 at 5 years, P ¼ 0.005, Figure 1c) , whereas there was a trend towards a significantly differing overall survival (0.95±0.05 vs 0.75±0.09 at 5 years, P ¼ 0.061, Figure 1d ). These data strongly suggest that neuroblastoma with loss of 11q comprises two distinct subsets with different clinical courses, which is mirrored by distinct gene expression patterns.
Global gene expression patterns differ in favourable and unfavourable neuroblastomas with loss of 11q We next analysed the relationship of clinical phenotypes, 11q aberrations and global gene expression patterns of the tumours. For this purpose, four neuroblastoma subgroups were defined according to 11q status (normal vs deletion/imbalance as determined using fluorescence in situ hybridization (FISH)) and the outcome of patients (event-free survivors for at least 2 years without any cytotoxic treatment vs metastatic or multiple loco-regional progression/relapse or death of disease). These clinical parameters were chosen to avoid biased results elicited by possible treatment influences on the natural courses of the disease. Tumours showing MYCN amplification and/or loss of 1p were excluded from the study because of their known or potential effect on gene expression profiles and the outcome of patients. According to these criteria, a total of 110 samples were selected from the cohort of our previous study .
At first, we applied unsupervised algorithm methods (principal component analysis and hierarchical clustering of unfiltered gene expression data) to determine the effects of the clinical phenotype and the 11q status on gene expression profiles independently of the clinicogenetic classification. Both principal component analysis and hierarchical clustering revealed that tumours group primarily according to their clinical phenotype (Figures 2a and b) . Most notably, favourable tumours with 11q loss (del11q_fav) did not associate with unfavourable tumours with 11q loss (del11q_unfav) but with favourable tumours without 11q loss (normal_-fav). A discriminatory effect of 11q CNA was observed only within the subgroup of unfavourable tumours, but not within the subgroup of favourable tumours. Unfavourable tumours without 11q loss (normal_unfav) were more associated with del11q_unfav than with normal_fav samples but did not build a delimited cluster on their own.
We next aimed to objectify these observations in a supervised analysis approach. Every subgroup was compared with each other by applying a method termed analysis of centroid distances, which is suitable to measure differences in overall gene expression patterns (Classen et al., 2007) . We calculated the pairwise Euclidean distances between all possible pairs of subgroups and determined their significance using permutation analysis. Highly significant differences (Po0.001 for each comparison, Figure 3) were observed between all groups except for the pair del11q_fav versus normal_fav (P ¼ 0.19). This finding corroborates the results of the unsupervised analyses, suggesting that favourable neuroblastomas with and without 11q loss do not differ in their overall gene expression profiles.
Identification of genes that are differentially expressed between clinico-genetic neuroblastoma subgroups To identify genes that are differentially expressed between the clinico-genetic subgroups, we performed significance analysis of microarrays (SAM; Table 1 and Table 3 ) and analysis of variance (ANOVA). In line with our above mentioned observations, only two and three genes were differentially expressed between favourable tumours with and without 11q loss by SAM and ANOVA, respectively (Po0.05 each). In contrast, expression profiles of favourable and unfavourable tumours with loss of 11q differed in 282 and 227 transcripts using SAM and ANOVA, respectively. Comparison of favourable versus unfavourable tumours without 11q aberrations revealed the largest number of differentially expressed genes (1187 and 322 transcripts as determined using SAM and ANOVA, respectively). In the cohort of tumours from patients with unfavourable outcome, subgroups with and without loss of 11q differed by 64 and 69 genes using SAM and ANOVA, respectively. On the basis of the SAM results, we next determined whether unfavourable tumours with and without 11q aberrations shared common features of gene expression in comparison with their favourable counterparts that may define their malignant phenotype. We observed 100 transcripts with a common differential expression between the subgroups normal_unfav versus normal_fav and del11q_unfav versus del11q_fav, corresponding to 35% of the mRNAs differing between the latter subtypes (Supplementary Figure 1a and Supplementary Table 4A ). It is noteworthy that all of these genes were regulated in the same direction in both comparisons, indicating their biological relevance in malignant progression of neuroblastoma. With one exception (HIST1H1C), all transcripts had lower expression levels in the unfavourable tumours. Among these mRNAs, genes were detected that have been described to be differentially regulated in benign and adverse neuroblastoma previously, such as FYN (Berwanger et al., 2002), MAP7 Oberthuer et al., 2006) and CAMTA1 (Henrich et al., 2006) . These data suggest that common mechanisms drive the malignant phenotype in both unfavourable neuroblastomas with and without 11q CNA.
We then asked whether expression levels of genes located on 11q were preferentially affected by loss of this chromosomal region using the SAM data (Table 1 and  Supplementary Table 3 ). The two genes that were differentially expressed between del11q_fav and normal_fav tumours were not located on chromosome 11q. In contrast, 27 of the 64 mRNAs (42%) that were differentially expressed between unfavourable neuroblastomas with and without loss of 11q were located on 11q, which is a significant enrichment of genes at this Figure 1 Kaplan-Meier estimates for event-free survival (EFS) and overall survival (OS) of neuroblastoma patients with 11q aberrations according to the prognostic prediction analysis for microarrays (PAM) gene signature in the whole cohort (n ¼ 61, a and b, respectively) and after exclusion of MYCN amplified tumours (n ¼ 55, c and d, respectively). Blue, favourable PAM prediction; red, unfavourable PAM prediction. A full colour version of this figure is available at the Oncogene journal online.
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À18
). As expected, most of these transcripts were downregulated in tumours of the del11q_unfav subgroup (24/27 genes). Comparison of del11q_fav and del11q_unfav tumours revealed 10/282 genes that were located on 11q (P ¼ 0.40), whereas comparison of normal_fav and normal_unfav tumours revealed an under-representation of genes located on 11q (38/1187 genes, P ¼ 0.01). These results indicate that loss of 11q affects the expression of genes located at this region, but only in neuroblastoma with an unfavourable phenotype.
We finally examined the number of genes that were differentially expressed between del11q_unfav and normal_fav tumours. The number of transcripts that were differentially expressed between these diametrically opposed subgroups was high (2470 genes), and significantly enriched for genes located on 11q (176 genes, 7%; Po10
À5
). We then determined the overlap of mRNAs that were differentially expressed between these subgroups and between the del11q_unfav versus del11q_fav tumours. If the latter tumours formed a homogeneous subgroup with normal_fav tumours, one would expect a large overlap of genes in these two comparisons. Indeed, 95% (269/282) of the genes of the comparison of del11q_unfav versus del11q_fav tumours were found in both analyses, all of which were regulated Table 4B) . Similarly, a large number of commonly regulated genes (51/64 genes, 80%) was found when the overlap of the comparisons normal_fav versus del11q_unfav and normal_unfav versus del11-q_unfav was determined (Supplementary Figure 1c and  Supplementary Table 4C) . Notably, genes located on 11q were consistently downregulated in del11q_unfav in comparison with both normal_unfav and normal_fav tumours, supporting the hypothesis that 11q loss does affect the expression of corresponding genes in unfavourable neuroblastoma.
Genomic aberrations at 11q comprise large chromosomal regions in both favourable and unfavourable neuroblastoma To rule out the possibility that our findings were influenced by substantial differences in the size of 11q
alterations, we performed array-based comparative genomic hybridization (aCGH) of those tumours with loss of 11q for which DNA was available (del11q_unfav, n ¼ 10; del11q_fav, n ¼ 6). Apart from an interstitial 53.3-Mb deletion of one tumour of the del11q_unfav subgroup (NB327), all aberrations represented large terminal deletions. Breakpoints clustered in two regions at 70-72 and 77-84 Mb, as reported previously (Stallings et al., 2006; Spitz et al., 2006b ). In the del11q_unfav subgroup, loss of terminal genomic material ranged from 54.8 to 64.0 Mb (62.2 Mb on average), whereas it ranged from 49.9 to 64.1 Mb in del11q_fav tumours (55.7 Mb on average, Figure 4a and Supplementary Integrated genomic profiling of neuroblastoma M Fischer et al noted that although deletions at 11q in the subgroup of del11q_unfav tumours were slightly larger on average than those of the del11q_fav subgroup, the largest terminal deletion of the whole cohort was observed in a del11q_fav tumour. These results argue against a significant influence of the size of the deleted region in determining the clinical phenotype of the tumour. In addition to 11q aberrations, almost all tumours of both the del11q_fav and the del11q_unfav subgroup were characterized by large 17q gains (Supplementary Table 5 ). These genomic alterations ranged from 41.2 to 56.1 Mb in the favourable subgroup (49.9 Mb on average), and from 39.6 to 55 Mb in the unfavourable subgroup (46.7 Mb on average). At a lower frequency, a gain of 17q was also found in tumours of both subgroups without 11q CNA (3/19 of normal_fav tumours and 2/5 of normal_unfav tumours). These data may indicate that a gain of 17q does not have an effect in addition to 11q loss on the determination of the clinical phenotype or on the gene expression profile of the tumour.
Promoter regions of differentially expressed genes located on 11q do not differ in their methylation status in clinico-genetic subgroups To determine whether epigenetic regulation by promoter hypermethylation might contribute to the specific gene expression profile of unfavourable neuroblastomas with loss of 11q, we finally analysed the methylation status of promoter regions from genes that were found to be downregulated in this subgroup. For this purpose, we selected 10 genes located at 11q, six of which had diminished expression levels in del11q_unfav in comparison with normal_unfav tumours, and four of which had lower mRNA levels in del11q_unfav in comparison with Schematic representation of deleted genomic regions at 11q in the del11q_fav and the del11q_unfav subgroups as determined using array-based comparative genomic hybridization (aCGH) (a). Case NB062, in which only a weak decrease in the signal strength at 11q was detected, is indicated by a grey bar. Hierarchical clustering of methylation ratios (b). A total of 425 CpG units of 10 genes located on 11q were analysed in 16 tumour samples (four of each subgroup). DNA-methylation values are indicated by colours ranging from dark red (non-methylated) to bright yellow (100% methylated). Poor-quality data are indicated in grey. A histogram is given in the inset that indicates the frequency of each colour in the hierarchical cluster analysis of this figure. For hierarchical clustering, Euclidian distance and complete linkage were used.
Integrated genomic profiling of neuroblastoma M Fischer et al del11q_fav tumours (Supplementary Table 6 ). In all, 22 genomic regions, ranging from 300 to 500 bp (median length, 432 bp), were analysed in four tumours of each subgroup (Supplementary Table 1) , and the methylation status of 425 CpG units was determined. In total, a strikingly homogeneous methylation pattern was observed in tumours of all subgroups, as indicated by an unsupervised hierarchical cluster analysis (Figure 4b ). The largest methylation differences were found in a region approximately 600 bp upstream of the DLG2 transcription start site, in which methylation ratios of four CpG units varied between 20 and 60%. In the remaining regions, methylation ratios did not differ considerably apart from outlying values of single CpG units. Although these results do not exclude the possibility that methylation of specific genes at 11q may contribute to the determination of the neuroblastoma phenotype, they indicate that the downregulation of multiple genes at 11q in del11q_unfav neuroblastoma does not result from global differences in CpG methylation patterns.
Discussion
Cancer genomes are characterized by numerous alterations including low-level copy number gains and losses of large chromosomal regions. Recurrent genomic CNA are thought to define distinct tumour subsets and contribute to tumourigenesis by affecting the expression of cancer genes. To identify such genes, transcriptomic patterns of tumours with and without the respective alterations have been compared in several studies. In most of these, the CNA under investigation were found to correlate with de-regulated gene expression of both the corresponding genes and global gene expression profiles (Pollack et al., 2002; Nigro et al., 2005; Chen et al., 2007; Yoshimoto et al., 2007; Gallegos Ruiz et al., 2008; Potter et al., 2008) . However, other studies did not observe such correlations between CNA and gene expression patterns (Platzer et al., 2002; Huang et al., 2006) . These heterogeneous results may be explained not only by the divergent biological behaviour of different malignancies in these studies, but also by the methodical difficulty to integrate CNA spanning hundreds of genes and the corresponding gene expression patterns in small tumour cohorts. In neuroblastoma, loss of large genomic regions at 11q occurs in roughly 30% of the tumours and is associated with an unfavourable clinical outcome. To evaluate the hypothesis that tumours with 11q CNA form a distinct clinico-genetic subgroup and to examine the effect of this genomic alteration on the transcriptome in vivo, we integrated clinical information, cytogenetic characteristics, gene expression profiles and promoter methylation data of neuroblastomas with and without loss of 11q. Classification of 61 neuroblastomas with 11q loss by our previously defined gene expressionbased classifier reliably distinguished tumours from patients with favourable and unfavourable outcome, suggesting that tumours with 11q CNA do not represent a homogeneous clinicogenetic subgroup of neuroblastoma. We next performed a more global assessment of the interactions of 11q CNA, gene expression patterns and the clinical phenotype by analysing four clinico-genetic subgroups defined according to the presence or absence of 11q CNA and the clinical outcome of the patients. Using both unsupervised and supervised analyses, it was shown that neuroblastoma with loss of 11q comprises two distinct subgroups that differ both in their clinical phenotype and their gene expression profile. Surprisingly, the gene expression profiles of tumours with 11q CNA from patients with a favourable disease did not deviate from benign tumours without 11q CNA. In contrast, unfavourable tumours with loss of 11q seem to constitute a specific subgroup and show downregulation of genes located at 11q in comparison with neuroblastoma without 11q CNA. Promoter methylation patterns of 10 genes showing downregulated expression in unfavourable tumours with 11q loss did not differ significantly among the four clinico-genetic subgroups. Together, these findings strongly suggest that 11q loss affects the expression levels of multiple corresponding genes in vivo in adverse neuroblastoma. In favourable neuroblastoma, however, the molecular effects of 11q loss are obviously compensated by yet unknown mechanisms.
As imbalances in 11q (that is, at least two intact copies of chromosome 11 but additional deleted copies) were present only in the subgroup of favourable neuroblastoma, one might suggest that these tumours may represent a more benign clinico-genetic subgroup in comparison with tumours with 11q deletions, and that the observed differences might be attributed to a less pronounced gene dosage effect. It has, however, been shown that patients with imbalances and patients with deletions of 11q do not differ in their clinical courses (Spitz et al., 2006a) . In addition, 3/7 tumours within the favourable subgroup with 11q loss showed hemizygous deletions at this genomic site, which clearly shows that our observations do not merely reflect different transcriptomic effects of either imbalances or deletions.
Current models of neuroblastoma pathogenesis propose two biologically different subtypes of the disease, based on the presence of recurrent CNA (Brodeur, 2003) : type 1 describes neuroblastoma with the capacity to spontaneously regress or to differentiate into benign ganglioneuroma and is characterized by numerical chromosomal alterations, whereas type 2 tumours follow an aggressive clinical course, and are further separated into two subtypes, 2A and 2B. Whereas type 2B is defined by an amplification of the oncogene MYCN, type 2A is mainly characterized by loss of chromosome 11q. According to this model, the phenotype of type 2A is conferred by 11q CNA, which has been suggested to downregulate the expression levels of one or multiple tumour suppressor genes in this region by haploinsufficiency or complex multigene repression mechanisms (Bilke et al., 2005; Maris et al., 2007; Stallings, 2007) . This hypothesis has been substantiated Integrated genomic profiling of neuroblastoma M Fischer et al by several studies that concurrently reported that loss of 11q affects the expression levels of multiple corresponding genes (McArdle et al., 2004; Wang et al., 2006; Lastowska et al., 2007; Mosse et al., 2007) . However, the sample numbers of these analyses were medium sized at most (n ¼ 22 -n ¼ 101), and in some of these, the data sets were dichotomized according to the cytogenetic aberrations under investigation, which renders the identification of subsets within a CNA-defined subgroup impossible. Notably, McArdle et al. (McArdle et al., 2004) observed that two low-stage tumours with loss of 11q grouped together with hyperdiploid low-stage tumours in a hierarchical cluster analysis. The researchers concluded from their data that loss of 11q (and gain of 17q) may be insufficient events to lead to a global gene expression profile indicative of aggressive stage 4 tumours, which is well in line with the results of our study.
In this study, we provide strong evidence that loss of 11q does not determine the phenotype of neuroblastoma by its own. It seems more likely that the decision between favourable and unfavourable neuroblastoma is made by yet undefined transforming events (for example, activating mutations in the tyrosine kinase ALK in a small subgroup; Mosse et al., 2008) previously to the acquirement of 11q loss and possibly also previously to the acquirement of other chromosomal alterations ( Figure 5 ). The biology of each subtype seems to be reflected accurately by the gene expression profile of the tumour cells. After the tumour phenotype has been specified, numerical aberrations occur primarily in the favourable subset, which might result from a mitotic defect in these tumours. Structural alterations (for example, 11q loss) may rarely arise in this subtype but do not contribute to the development of aggressive tumours. In contrast, a defect in genomic stability may represent an inherent property of unfavourable neuroblastoma, leading to multiple structural aberrations at fragile genomic sites. Selective pressure on the cancer cells may then promote the development of a tumour subset with 11q loss, whereas the presence of MYCN amplification seems to be almost incompatible with 11q CNA. The effect of 11q loss can be recognized in the transcriptome of unfavourable neuroblastoma and may contribute to specific properties of this subtype. In favourable tumours, however, the effects of diminished gene dosages caused by 11q CNA are obviously balanced by molecular mechanisms yet to be determined.
In line with the proposed model, we observed unfavourable tumours without any detectable structural genomic alterations (Supplementary Table 5) , and a substantial concordance of differentially expressed genes between unfavourable and favourable tumours, regardless of the presence of CNA at 11q and other sites (Supplementary Figure 1a) . These findings corroborate the notion of a common mechanism of malignant transformation in aggressive neuroblastoma. Alternatively, it is possible that loss of 11q represents a first hit in neuroblastoma tumourigenesis and that favourable tumours with 11q CNA constitute an intermediate stage of aggressive neuroblastoma development before a second transforming event. This notion might be supported by the fact that Figure 5 Proposed model of neuroblastoma tumourigenesis modified after Brodeur (2003) . The biological and clinical phenotype of neuroblastoma is determined at an early stage of tumour development and is reflected by distinct gene expression patterns. Afterwards, structural genomic alterations occur preferentially in the unfavourable subgroup and may contribute to specific properties of the tumour cells. However, structural alterations may also occasionally occur in the favourable subgroup, in which they are silent events. As an exception, amplification of MYCN may represent an early event of tumourigenesis.
Integrated genomic profiling of neuroblastoma M Fischer et al 4/7 tumours of the del11q_fav subgroup were detected in the neuroblastoma mass screening program. However, as favourable tumours are known to rarely develop into unfavourable neuroblastoma (Brodeur, 2003) , this hypothesis seems to be rather unlikely.
It is important to emphasize that this study did not aim at evaluating the prognostic significance but the biological relevance of 11q loss for the pathogenesis of neuroblastoma. It has been shown in large patient cohorts that loss of 11q is statistically associated with adverse clinical courses (Attiyeh et al., 2005; Spitz et al., 2006a) . Nevertheless, our results provide further evidence that gene expression patterns are strongly correlated with the biological and clinical behaviour in neuroblastoma (Ohira et al., 2005; Asgharzadeh et al., 2006; Oberthuer et al., 2006 Oberthuer et al., , 2008 . In general, our study shows that the presence of prognostically meaningful genomic aberrations does not necessarily form a homogeneous clinico-genetic subgroup of cancer, and exemplifies that integration of detailed clinical information of the patients with genetic, transcriptomic and epigenetic characteristics of the tumours can contribute to the establishment of models for tumour development.
Materials and methods

Characteristics of patients and tumours
In this study, analyses were performed in two patient cohorts that were defined by different criteria: (1) For analysis of the power of the PAM classifier to predict the outcome of patients with tumours showing 11q CNA, all available tumours with loss of 11q, as determined using FISH, were analysed (total, n ¼ 61; deletion, n ¼ 44; imbalance, n ¼ 17; stage 1, n ¼ 8; stage 2, n ¼ 4; stage 3, n ¼ 5; stage 4, n ¼ 40; stage 4S, n ¼ 4; MYCN amplification, n ¼ 6; loss of 1p, n ¼ 19, 1p status not evaluable in 1 case). Patients were enrolled in the German neuroblastoma trials NB90-NB04 with informed consent. Median age at diagnosis was 31 months, and the median follow-up of patients who were alive was 56 months. (2) For the comparison of clinico-genetic subgroups, we selected all available tumours (total, n ¼ 110; stage 1, n ¼ 50; stage 2, n ¼ 24; stage 3, n ¼ 5; stage 4, n ¼ 14; stage 4S, n ¼ 17) from our previously described expression array cohort ) that fitted to the following clinical and genomic criteria: (i) Samples from patients with clinical courses defined as either survival without event for at least 2 years without any chemotherapy (n ¼ 88, referred to as 'favourable' throughout the paper), or as progression/relapse into stage 4 (n ¼ 7), multiple loco-regional relapses (n ¼ 1) or death of disease (n ¼ 14), which were in total referred to as 'unfavourable'. (ii) In addition, the selected tumours were characterized by either the presence (n ¼ 21) or the absence of loss of 11q (n ¼ 89) according to FISH analysis. Tumours with MYCN amplification or loss of 1p were intentionally excluded from these sets. All patients were enrolled in the German neuroblastoma trials NB90-NB97 with informed consent. Median age at diagnosis was 14 months, and median follow-up of patients who were alive was 89 months. The characteristics of the patients and tumours are summarized in Supplementary Table 1 .
Fluorescence in situ hybridization (FISH) analyses CNA of the chromosome arms 1p, 11q and the MYCN status were determined by interphase FISH, as described elsewhere (Spitz et al., 2003) , using the DNA probes D1Z2 (1p36), n-myc (2p24) and MLL (11q23), together with the centromeric probes D1Z1, D2Z and D11Z1, respectively. Cell nuclei were counterstained using 4,6-diamidino-2-phenylindole. According to the ENQUA guidelines (Ambros and Ambros, 2001), chromosomal aberrations were defined as deletion by monosomy of the specific region, imbalance by at least two intact copies of the chromosome and additional copies with deletions in the specific region and MYCN amplification by at least a fivefold increase in MYCN signal numbers in relation to the number of chromosome 2.
Gene expression profiling analyses Gene expression profiling experiments were carried out using a customized neuroblastoma-related oligonucleotide microarray (Agilent Technologies, Santa Clara, CA, USA) that comprised 10 163 probes covering 8155 Unigene clusters. A total of 486 of the probes on the microarray refer to genes annotated on chromosome 11q. Expression profiles from each neuroblastoma sample were generated as dye-flipped duplicates in dualcolour experiments as described elsewhere . Data from dye-flipped chip pairs were averaged to yield one intensity value for every gene probe of each patient after quality control of raw microarray data and normalization of expression profiles had been performed. All microarray data are available at the ArrayExpress database (http://www.ebi. ac.uk/arrayexpress accession: E-TABM-38).
Array-based comparative genomic hybridization (aCGH) High-resolution oligonucleotide aCGH was performed using either 44 or 105 K microarrays (43 000 and 99 000 human sequence probes, respectively) as described elsewhere (Spitz et al., 2006b) . In brief, 2.5-5 mg genomic tumour and reference DNA were labelled and processed according to the manufacturer protocol for each hybridization (Agilent Technologies) and scanned. Images were extracted using Feature Extraction 9.5 software and visualized using CGH-Analytics 3.5 software (Agilent Technologies). The boundaries of chromosome gains and losses were delineated using the ADM-2 algorithm of the CGH-Analytics software.
Analysis of the methylation status of promoter regions Analysis of the methylation pattern of DNA promoter regions was performed by Sequenom Inc. (Hamburg, Germany) as described elsewhere (Ehrich et al., 2005) . In brief, 1 mg genomic DNA of each sample was treated with sodium bisulphite using EZ-96 DNA methylation kit according to the alternative conversion protocol of the manufacturer (Zymo Research, Orange, CA, USA). Genomic regions of interest were amplified by PCR using reverse primers that incorporate the T7 promoter sequence for in vitro transcription. Oligonucleotides used as primers were designed by using Methprimer (www.urogene.org/methprimer/, Supplementary Table 2 ). Quantitative methylation analysis was then performed using Sequenom's MassARRAY platform, which uses MALDI-TOF mass spectrometry in combination with RNA basespecific cleavage (MassCLEAVE). Mass spectra were acquired by using a MassARRAY Compact MALDI-TOF (Sequenom) and spectra's methylation ratios were generated using the Epityper software 1.0 (Sequenom).
Bioinformatics and statistical analyses
For survival analysis, Kaplan-Meier estimates were calculated and compared by log rank-test. Death resulting from therapy complications was censored for event-free survival and overall
Integrated genomic profiling of neuroblastoma M Fischer et al survival analysis. Progression, relapse and death from disease were considered as events. PCA and hierarchical clustering of expression data were performed using the Rosetta Resolver Software (Version 7.2; Rosetta Inpharmatics LCC, Seattle, WA, USA). Pairwise comparison of centroid distances in global gene expression patterns was performed in three steps (Classen et al., 2007) . First, the group mean expression values were calculated for each gene. Next, the distances between the mean values were quantified for each gene in the two groups under investigation using the Euclidean distance. The centroid distance between two groups is defined as the sum of distances for all genes. Finally, the significance of the calculated centroid distance of all group-pairs was analysed. The group labels were randomly permuted 10 000 times followed by a recalculation of centroid distances. The P-value is given by the fraction of iterations that yield centroid distances at least as great as the original centroid distance between two groups. To determine differentially expressed genes, pairwise comparison of subgroups were performed using one-way ANOVA with Benjamini-Hochberg correction for multiple testing (Rosetta Resolver Software) and SAM (Tusher et al., 2001 ) with the samr package v1.23 for R open-source software (http:// www.R-project.org). The SAM statistics was computed with 1000 permutations and the D-value chosen for a 90th percentile false-discovery rate o0.05. Fisher's exact test was applied to analyse for an enrichment of differentially expressed genes on 11q against the null hypothesis that differentially expressed genes are randomly distributed over all chromosomes. The quantitative methylation data were analysed in an unsupervised hierarchical clustering using the Euclidian distance and complete linkage. All calculations were performed using the gplots, Hmisc, lattice and gmodels package in R. Hypothesisbased significance testing was evaded, because the observed differences were negligible.
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